Erkut Borazanci, MD
Enriched profileMedical Director of the Oncology Research Division, HonorHealth Research Institute · HonorHealth Research Institute
Erkut Borazanci is Medical Director of the Oncology Research Division, HonorHealth Research Institute at HonorHealth Research Institute. OpenAlex indexes 328 publications with 4,703 citations (h-index 28); ClinicalTrials.gov lists 17 registered studies with this person as an investigator.
Data verified 11 Oct 2026
Overview
Updated 16 Oct 2026
Erkut Borazanci, MD, MS, is Medical Director of the Oncology Research Division, HonorHealth Research Institute. The public record shows 328 publications with 4,703 citations (h-index 28), centered on Pancreatic and Hepatic Oncology Research, Pancreatitis Pathology and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 17 registered clinical trials, industry payments reported by 5 companies.
- Top research focus: Pancreatic and Hepatic Oncology Research
- 17 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 53.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 17 registered studies on ClinicalTrials.gov. The most recent:
- Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Sponsor: EXACT Therapeutics AS
- Pancreatic Cancer Detection Consortium
Sponsor: City of Hope Medical Center
- Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
Sponsor: Qualigen Theraputics, Inc.
Industry payments
Updated 16 Oct 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202512 payments$17,897openpaymentsdata.cms.gov ↗
- Partner Therapeutics, Inc.Program year20254 payments
- TAIHO ONCOLOGY, INC.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.6%Serotonin-3 Receptor Antagonist20%Ondansetron Odt100%Part D≥18 patientsAntidiarrheal microorganisms16.2%Creon100%Part D<11 patients+ 1 more class in this area
Nervous system
22.3%Opioid Agonist13.1%Oxycodone Hcl100%Part D≥12 patientsAtypical Antipsychotic9.2%Olanzapine100%Part D<11 patientsSensory organs
17.7%Corticosteroid17.7%Dexamethasone100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
120 congress contributions (2014–2026) across AACR, ASCO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 2226: Novel targeted therapies for malignant ascites in pancreatic cancer.
AACR Annual Meeting
AACR2026Co-author - Abstract 2526: Non-invasive biomarker discovery and validation for the early detection of pancreatic cancer
AACR Annual Meeting
AACR2026Co-author - Abstract 6497: Synergistic disruption of KRAS and FAK pathways: A preclinical pipeline for PDAC therapy optimization
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A super-enhancer-regulated RNA-binding protein cascade drives pancreatic cancer
Nature Communications
2023
Most-cited works
by citation count (OpenAlex)- 01
- 02Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoringArticle429 citations2019
- 03
- 04Triptolide and Its Derivatives as Cancer TherapiesReview311 citations2019
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/erkut-borazanci-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/erkut-borazanci-a65aaaa9
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Erkut-Borazanci
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Spotify
creators.spotify.com/pod/profile/seena-magowitz-foundation/episodes/GRAND-SLAM-Trial-Results-Just-Now-Released---Pancreatic-Cancer-Podcast---Dr--Borazanci-e18c5nj
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →creators.spotify.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
LSU Health School of Medicine - Shreveport
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →honorhealth.com ↗ - Board certified in Medical Oncology
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →honorhealth.com ↗
Secondary affiliations
appointments beyond the home institution- Translational Genomics Research Institute (TGen)
adjunct clinical faculty
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →honorhealth.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH